Anti-allergy agent containing compound plant anti-allergy active ingredients as well as preparation method and application of anti-allergy agent

Abstract

The invention is suitable for the technical field of anti-allergy agents, and provides an anti-allergy agent containing compound plant anti-allergy active ingredients. Comprising 5-10 parts of a bletilla striata extract, 8-15 parts of an aloe extract, 7-12 parts of an angelica sinensis extract, 10-20 parts of a centella asiatica extract, 5-15 parts of a rosemary extract, 8-18 parts of a polygonum cuspidatum extract, 12-25 parts of a scutellaria baicalensis extract, 3-10 parts of a tea extract, 6-15 parts of a liquorice extract and 4-12 parts of a matricaria recutita extract. The preparation method of the anti-allergy agent containing the compound plant anti-allergy active ingredients comprises the following steps: step 1, extracting and concentrating in groups; step 2, compounding additional ingredients; and step 3, mixing and forming the preparation. The anti-allergy agent containing the compound plant anti-allergy active component is specifically applied to allergic rhinitis nasal spray, postoperative wound repair, pet skin anti-allergy spray, anti-allergy baby clothes treating agent, low-allergy household cleaning agent and air purification spray. And through the synergistic effect of multiple targets and multiple channels, the balanced synergism of the repairing effect and the relieving effect is realized.

Description

Technical Field

[0001] The present invention relates to the technical field of anti-allergic agents, and particularly to an anti-allergic agent containing compound plant anti-allergic active ingredients, a preparation method and an application thereof. Background Art

[0002] The research and development of anti-allergic agents stems from the market pain points of the dependence of traditional anti-allergic products on chemical hormones and the single efficacy of natural ingredients. With the increasing demand of consumers for the coordination of safety and efficacy, a compound plant anti-allergic agent with centella asiatica, rosemary, polygonum cuspidatum, scutellaria baicalensis, tea, licorice, and chamomilla recutita as the core has emerged. At present, a mature technical system has been formed in this field.

[0003] However, the effects of centella asiatica and scutellaria baicalensis have not been truly released in the compound plant anti-allergic agent with "centella asiatica, rosemary, polygonum cuspidatum, scutellaria baicalensis, tea, licorice, and chamomilla recutita" as the core. For example, scutellaria baicalensis regulates the NF-κB inflammatory pathway and reduces the release of the pro-inflammatory factor TNF-α.

[0004] Therefore, in view of the above problems, an anti-allergic agent containing compound plant anti-allergic active ingredients, a preparation method and an application thereof are specifically proposed. Summary of the Invention

[0005] The purpose of the embodiments of the present invention is to provide an anti-allergic agent containing compound plant anti-allergic active ingredients, a preparation method and an application thereof, aiming to solve the problem that the effects of centella asiatica and scutellaria baicalensis have not been truly released in the compound plant anti-allergic agent with "centella asiatica, rosemary, polygonum cuspidatum, scutellaria baicalensis, tea, licorice, and chamomilla recutita" as the core. For example, scutellaria baicalensis regulates the NF-κB inflammatory pathway and reduces the release of the pro-inflammatory factor TNF-α.

[0006] Specifically, the anti-allergic agent containing compound plant anti-allergic active ingredients includes the following components in parts by weight: 5-10 parts of bletilla striata extract, 8-15 parts of aloe vera extract, 7-12 parts of angelica sinensis extract, 10-20 parts of centella asiatica extract, 5-15 parts of rosemary extract, 8-18 parts of polygonum cuspidatum extract, 12-25 parts of scutellaria baicalensis extract, 3-10 parts of tea extract, 6-15 parts of licorice extract, and 4-12 parts of chamomilla recutita extract; Among them, the polysaccharide component of the bletilla striata extract is used to synergistically enhance the skin barrier repair ability with the centella asiatica extract and promote epidermal cell regeneration; the aloe vera extract is used to combine with the chamomilla recutita extract to inhibit skin erythema through anti-inflammatory activity and improve the moisturizing effect at the same time; the angelica sinensis extract is used to synergistically regulate the NF-κB inflammatory pathway with the scutellaria baicalensis extract, reduce the release of the pro-inflammatory factor TNF-α, and strengthen the repair effect.

[0007] Therefore, the addition of Bletilla striata, Aloe vera, and Angelica sinensis forms a synergistic effect with the original components in a specific ratio. For example, Bletilla striata polysaccharide and asiaticoside of Centella asiatica jointly promote the migration of keratinocytes, emodin of Aloe vera and matricaria lactone inhibit the histamine release pathway, and ferulic acid of Angelica sinensis and baicalin jointly regulate the inflammatory signaling pathway.

[0008] The technical solutions of the present application will be further described below: In one embodiment, an anti-allergy agent containing compound plant anti-allergy active ingredients includes the following components in parts by weight: 8 parts of Bletilla striata extract, 10 parts of Aloe vera extract, 9 parts of Angelica sinensis extract, 15 parts of Centella asiatica extract, 10 parts of Rosmarinus officinalis extract, 12 parts of Polygonum cuspidatum extract, 20 parts of Scutellaria baicalensis extract, 7 parts of tea extract, 10 parts of Glycyrrhiza glabra extract, and 8 parts of Matricaria chamomilla extract.

[0009] Therefore, Centella asiatica, Rosmarinus officinalis, and Polygonum cuspidatum are the core repair components, which promote the regeneration of the skin barrier through multiple targets; asiaticoside of Centella asiatica activates the TGF-β pathway and stimulates collagen synthesis, synergistically enhancing the repair of the dermis with resveratrol of Polygonum cuspidatum. At the same time, Polygonum cuspidatum enhances antioxidant defense through the Nrf2 pathway and reduces the damage of free radicals to the barrier; rosmarinic acid of Rosmarinus officinalis inhibits collagen-degrading enzymes and protects the integrity of the extracellular matrix. Its antioxidant ability forms a synergistic network with EGCG in tea, prolongs the repair activity, and reduces photoaging damage; Glycyrrhiza glabra protects skin moisturizing factors by inhibiting hyaluronidase, and jointly enhances the water-holding capacity of the stratum corneum with the polysaccharide component of Centella asiatica, reducing transepidermal water loss; Scutellaria baicalensis, Matricaria chamomilla, Glycyrrhiza glabra, and tea focus on anti-inflammation and sedation, blocking the allergic reaction through multiple pathways; baicalin of Scutellaria baicalensis inhibits the NF-κB inflammatory pathway and reduces the release of TNF-α, synergistically blocking mast cell degranulation with matricaria lactone of Matricaria chamomilla, reducing the histamine release by 60%-70%, and quickly relieving redness, swelling, and itching; bisabolol of Matricaria chamomilla directly inhibits the histamine receptor, jointly down-regulates the release of substance P with glycyrrhizic acid of Glycyrrhiza glabra, reducing neurogenic sensitivity, and reducing the burning sensation within 10 minutes; tea polyphenols and baicalin in tea jointly inhibit the production of nitric oxide, neutralize reactive oxygen species in the allergic reaction, and block the amplification of the inflammatory cascade, while resveratrol of Polygonum cuspidatum reduces the production of prostaglandin E2 by regulating the expression of COX-2, preventing the deterioration of chronic sensitivity; through the synergistic effect of multiple targets and multiple pathways, the balance and enhancement of the repair effect and the soothing effect are jointly achieved.

[0010] In one embodiment, an anti-allergy agent containing compound plant anti-allergy active ingredients further includes the following components in parts by weight: 8-12 parts of Dendrobium officinale extract and 6-10 parts of Morus alba root bark extract.

[0011] Furthermore, an anti-allergy agent containing compound plant anti-allergy active ingredients further includes the following components in parts by weight: 10 parts of Dendrobium officinale extract and 8 parts of Morus alba root bark extract.

[0012] In one embodiment, an anti-allergy agent containing a compound plant anti-allergy active ingredient. The polysaccharide of the dendrobium extract activates the AQP3 aquaporin to increase the epidermal water content, and synergistically enhances moisturization with the hyaluronidase inhibition of licorice; the dendrobine of the dendrobium extract inhibits the over-activation of the TRPV1 receptor to relieve the burning sensation, and forms a double neural calming pathway with the bisabolol of chamomile; Mulberroside of the mulberry bark extract inhibits the release of tryptase from mast cells, and synergistically reduces the itching frequency with the histamine-blocking effect of chamomile; the resveratrol oxide of the mulberry bark extract has 2 times the ROS-scavenging ability of ordinary resveratrol, and jointly extends the antioxidant duration with EGCG of tea.

[0013] Another object of the present invention is to provide a preparation method of an anti-allergy agent containing a compound plant anti-allergy active ingredient, comprising the following steps: Step 1: Group extraction and concentration S1. Extract centella asiatica, rosemary and polygonum cuspidatum by alcohol extraction Weigh centella asiatica, rosemary and polygonum cuspidatum by weight, mix evenly; add 60% ethanol aqueous solution 6-8 times the total mass of the raw materials, reflux extract at 70-75 °C for 2 times, 2 h each time; combine the two extraction solutions, filter through a 0.45 μm filter membrane to obtain an alcohol extract; concentrate the alcohol extract under reduced pressure at 60 °C to a relative density of 1.15-1.20 to obtain an alcohol extract paste; spray dry under the conditions of an inlet air temperature of 160 °C and an outlet air temperature of 80 °C to make an alcohol extract powder; S2. Extract scutellaria baicalensis, tea, licorice and chamomile by water extraction Weigh scutellaria baicalensis, tea, licorice and chamomile by weight; add 10 times the mass of deionized water to each raw material, decoct at 80-85 °C for 3 h, and filter while it is hot; combine the filtrates of scutellaria baicalensis, tea, licorice and chamomile, purify through macroporous adsorption resin of model AB-8 to remove impurities; concentrate to a solid content of not less than 30% by weight percentage to obtain a water extract paste; Step 2: Compound additional components Select any one of the following components for compounding according to requirements to enhance the repair or soothing effect: S1. Repair enhancement group Add bletilla striata extract, mix with centella asiatica in the alcohol extraction component in a ratio of 1:2-1:3, and synergistically promote the synthesis of stratum corneum lipids through β-glucan and asiaticoside; extract the bletilla striata tuber by water extraction at 80-95 °C, ultrafilter after extracting for 4 h, with a cut-off molecular weight of 10 kDa, and concentrate to a polysaccharide content of not less than 50%; S2. Soothing enhancement group Add aloe extract, mix it with chamomile extract in a ratio of 2:1 - 3:1, and use emodin to inhibit the COX-2 inflammatory pathway; after freeze-drying aloe gel, extract it with 50% ethanol by ultrasonic wave for 25 - 35 min at an ultrasonic power of 300W to remove the irritating anthraquinone components; S3, Anti-inflammatory Synergy Group Add angelica extract, jointly regulate the NF-κB pathway with scutellaria extract, and inhibit the release of TNF-α; percolate and extract angelica root with 70% ethanol, concentrate it, and separate ferulic acid by silica gel column chromatography to make the purity exceed 90%.

[0014] Furthermore, before performing the grouped extraction and concentration in Step 1, select dry whole centella asiatica herb, rosemary leaves, polygonum cuspidatum roots, scutellaria roots, tea leaves, licorice roots, and chamomile flowers, wash them respectively, dry them in a low-temperature environment of 40 - 50 °C, and control the moisture content not to exceed 8%; crush the whole centella asiatica herb, rosemary leaves, polygonum cuspidatum roots, scutellaria roots, tea leaves, licorice roots, and chamomile flowers into 20 - 40 mesh particles.

[0015] Furthermore, before performing the grouped extraction and concentration in Step 1, select dry whole centella asiatica herb, rosemary leaves, polygonum cuspidatum roots, scutellaria roots, tea leaves, licorice roots, and chamomile flowers, wash them respectively, dry them in a low-temperature environment of 45 °C, and control the moisture content not to exceed 8%; crush the whole centella asiatica herb, rosemary leaves, polygonum cuspidatum roots, scutellaria roots, tea leaves, licorice roots, and chamomile flowers into 33 - 37 mesh particles.

[0016] Furthermore, in the compounding of additional components in Step 2, select any one of the following components for compounding according to needs to enhance the repair or soothing effect: S1, Repair Enhancement Group Add bletilla striata extract, mix it with centella asiatica in the alcohol extraction component in a ratio of 1:2 - 1:3, and synergistically promote the synthesis of stratum corneum lipids through β-glucan and asiaticoside; extract bletilla striata tubers with water at a temperature of 90 °C, ultrafilter after extracting for 4 h, with a cut-off molecular weight of 10 kDa, and concentrate to a polysaccharide content of not less than 50%; S2, Soothing Enhancement Group Add aloe extract, mix it with chamomile extract in a ratio of 2:1 - 3:1, and use emodin to inhibit the COX-2 inflammatory pathway; after freeze-drying aloe gel, extract it with 50% ethanol by ultrasonic wave for 30 min at an ultrasonic power of 300W to remove the irritating anthraquinone components; S3, Anti-inflammatory Synergy Group Add angelica extract, jointly regulate the NF-κB pathway with scutellaria extract, and inhibit the release of TNF-α; percolate and extract angelica root with 70% ethanol, concentrate it, and separate ferulic acid by silica gel column chromatography to make the purity exceed 90%.

[0017] Application of an anti-allergy agent containing compound plant anti-allergy active ingredients. The anti-allergy agent containing compound plant anti-allergy active ingredients with an addition amount of 1% - 15% of the total mass is applied to allergic rhinitis nasal sprays, postoperative wound repair, pet skin anti-allergy sprays, anti-allergy baby clothing treatment agents, low-allergy household cleaners, and air purification sprays.

[0018] Compared with the prior art, the present invention can achieve the following: 1. The addition of Bletilla striata, Aloe vera, and Angelica sinensis forms a synergistic effect with the original components in a specific ratio. For example, the polysaccharide component of Bletilla striata extract synergistically enhances the skin barrier repair ability with Centella asiatica extract and promotes epidermal cell regeneration; Aloe vera extract combined with Matricaria chamomilla extract inhibits skin erythema through anti-inflammatory activity and improves the moisturizing effect at the same time; Angelica sinensis extract and Scutellaria baicalensis extract synergistically regulate the NF-κB inflammatory pathway, reduce the release of pro-inflammatory factor TNF-α, and strengthen the repair effect. That is, Bletilla striata polysaccharide and Centella asiatica saponin jointly promote the migration of keratinocytes, aloe-emodin and chamazulene inhibit the histamine release pathway, and ferulic acid of Angelica sinensis and baicalin of Scutellaria baicalensis jointly regulate the inflammatory signaling pathway; through the synergistic effect of multiple targets and multiple pathways, the balance and synergy of the repair effect and the soothing effect are jointly achieved. 2. Centella asiatica, Rosmarinus officinalis, and Polygonum cuspidatum are the core repair components, which promote the regeneration of the skin barrier through multiple targets; asiaticoside of Centella asiatica activates the TGF-β pathway and stimulates collagen synthesis, synergistically enhancing the repair of the dermis with resveratrol of Polygonum cuspidatum. At the same time, Polygonum cuspidatum enhances antioxidant defense through the Nrf2 pathway and reduces the damage of free radicals to the barrier; rosmarinic acid of Rosmarinus officinalis inhibits collagen-degrading enzymes and protects the integrity of the extracellular matrix. Its antioxidant ability forms a synergistic network with EGCG in tea, prolongs the repair activity, and reduces photoaging damage; Glycyrrhiza glabra protects skin moisturizing factors by inhibiting hyaluronidase and jointly improves the water hydration ability of the stratum corneum with the polysaccharide component of Centella asiatica, reducing transepidermal water loss; Scutellaria baicalensis, Matricaria chamomilla, Glycyrrhiza glabra, and tea focus on anti-inflammation and sedation, blocking the allergic reaction through multiple pathways; baicalin of Scutellaria baicalensis inhibits the NF-κB inflammatory pathway and reduces the release of TNF-α, synergistically blocking mast cell degranulation with chamazulene of Matricaria chamomilla, reducing the histamine release by 60% - 70%, and quickly relieving redness, swelling, and itching; bisabolol of Matricaria chamomilla directly inhibits histamine receptors, jointly downregulates the release of substance P with glycyrrhizic acid of Glycyrrhiza glabra, reduces neurogenic sensitivity, and relieves the burning sensation within 10 minutes; tea polyphenols and baicalin jointly inhibit nitric oxide production, neutralize reactive oxygen species in the allergic reaction, and block the amplification of the inflammatory cascade, while resveratrol of Polygonum cuspidatum prevents the deterioration of chronic sensitivity by regulating the expression of COX-2 and reducing the production of prostaglandin E2. 3. The polysaccharides in the Dendrobium extract activate the AQP3 aquaporin to increase the epidermal water content, and synergistically enhance moisturization with the hyaluronidase inhibition of licorice; the dendrobine in the Dendrobium extract inhibits the overactivation of TRPV1 receptors to relieve the burning sensation, and forms a double neural calming pathway with the bisabolol of chamomile; the morusin in the mulberry bark extract inhibits the release of tryptase from mast cells, and synergistically reduces the itching frequency with the histamine blocking effect of chamomile; the resveratrol oxide in the mulberry bark extract has twice the ability to scavenge ROS as ordinary resveratrol, and jointly extends the antioxidant duration with EGCG in tea. 4. Combine the blood vessel repair of Sanguisorba officinalis with the epidermal regeneration of Lithospermum erythrorhizon, target the linkage repair of "deep inflammation - superficial injury", and break through the traditional single anti-inflammatory or collagen-promoting ideas. Description of the Drawings

[0019] Figure 1 It is the cell viability graph in the test of Example 4; Figure 2 It is the bar graph of the IL-1α content in the test of Example 4; Figure 3 It is the bar graph of the IL-6 content in the test of Example 4; Figure 4 It is the bar graph of the TNF-α content in the test of Example 4; Figure 5 It is the summary graph of the cell migration results in the test of Example 4; Figure 6 It is the bar graph of the cell healing rate in the test of Example 4; Figure 7 It is the bar graph of the IL-1α content in the test of Example 1; Figure 8 It is the bar graph of the IL-6 content in the test of Example 1; Figure 9 It is the bar graph of the TNF-α content in the test of Example 1; Figure 10 It is the bar graph of the cell healing rate in the test of Example 1; Figure 11 It is the bar graph of the IL-1α content in the test of Example 6; Figure 12 It is the bar graph of the IL-6 content in the test of Example 6; Figure 13 It is the bar graph of the TNF-α content in the test of Example 6; Figure 14 It is the bar graph of the cell healing rate in the test of Example 6. Detailed Implementation Modes

[0020] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention will be further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention. The specific implementation of the present invention will be described in detail below with reference to specific embodiments.

[0021] Example 1 An anti-allergy agent containing a compound plant anti-allergy active ingredient, comprising the following components in parts by weight: 5 parts of Bletilla striata extract, 8 parts of Aloe vera extract, 7 parts of Angelica sinensis extract, 10 parts of Centella asiatica extract, 5 parts of Rosmarinus officinalis extract, 8 parts of Polygonum cuspidatum extract, 12 parts of Scutellaria baicalensis extract, 3 parts of tea extract, 6 parts of Glycyrrhiza glabra extract, and 4 parts of Matricaria chamomilla extract.

[0022] Therefore, the addition of Bletilla striata, Aloe vera, and Angelica sinensis forms a synergistic effect with the original components in a specific ratio.

[0023] Example 2 An anti-allergy agent containing a compound plant anti-allergy active ingredient, comprising the following components in parts by weight: 10 parts of Bletilla striata extract, 15 parts of Aloe vera extract, 12 parts of Angelica sinensis extract, 20 parts of Centella asiatica extract, 15 parts of Rosmarinus officinalis extract, 18 parts of Polygonum cuspidatum extract, 25 parts of Scutellaria baicalensis extract, 10 parts of tea extract, 15 parts of Glycyrrhiza glabra extract, and 12 parts of Matricaria chamomilla extract.

[0024] Example 3 An anti-allergy agent containing a compound plant anti-allergy active ingredient, comprising the following components in parts by weight: 8 parts of Bletilla striata extract, 10 parts of Aloe vera extract, 9 parts of Angelica sinensis extract, 15 parts of Centella asiatica extract, 10 parts of Rosmarinus officinalis extract, 12 parts of Polygonum cuspidatum extract, 20 parts of Scutellaria baicalensis extract, 7 parts of tea extract, 10 parts of Glycyrrhiza glabra extract, and 8 parts of Matricaria chamomilla extract.

[0025] The polysaccharide component of the Bletilla striata extract is used to synergistically enhance the skin barrier repair ability with the Centella asiatica extract and promote epidermal cell regeneration; the Aloe vera extract is used to combine with the Matricaria chamomilla extract to inhibit skin erythema through anti-inflammatory activity and improve the moisturizing effect at the same time; the Angelica sinensis extract is used to synergistically regulate the NF-κB inflammatory pathway with the Scutellaria baicalensis extract, reduce the release of pro-inflammatory factor TNF-α, and strengthen the repair effect.

[0026] Therefore, centella asiatica, rosemary, and polygonum cuspidatum are the core repair ingredients, which promote skin barrier regeneration through multiple targets; asiaticoside in centella asiatica activates the TGF-β pathway, stimulates collagen synthesis, and synergistically enhances dermal layer repair with resveratrol in polygonum cuspidatum. At the same time, polygonum cuspidatum enhances antioxidant defense through the Nrf2 pathway, reducing the damage of free radicals to the barrier; rosmarinic acid in rosemary inhibits collagen-degrading enzyme (MMP-1), protects the integrity of the extracellular matrix, its antioxidant ability forms a synergistic network with EGCG in tea, prolongs the repair activity, and reduces photoaging damage; licorice protects skin moisturizing factors by inhibiting hyaluronidase, and together with the polysaccharide component of centella asiatica, enhances the water hydration ability of the stratum corneum, reducing transepidermal water loss (TEWL); scutellaria baicalensis, chamomilla recutita, licorice, and tea focus on anti-inflammatory and calming effects, blocking sensitive reactions through multiple pathways; baicalin in scutellaria baicalensis inhibits the NF-κB inflammatory pathway, reduces the release of TNF-α, and synergistically blocks mast cell degranulation with matricin in chamomilla recutita, reducing the histamine release by 60%-70% and quickly relieving swelling, redness, and itching; bisabolol in chamomilla recutita directly inhibits the histamine receptor (H1R), and together with glycyrrhizic acid in licorice, downregulates the release of substance P, reducing neurogenic sensitivity and reducing the burning sensation within 10 minutes; tea polyphenols and baicalin in tea jointly inhibit the production of nitric oxide (NO), neutralize reactive oxygen species (ROS) in allergic reactions, block the amplification of the inflammatory cascade, while resveratrol in polygonum cuspidatum reduces the production of prostaglandin E2 (PGE2) by regulating the expression of COX-2, preventing the deterioration of chronic sensitivity; through the synergistic effects of multiple targets and multiple pathways, the balance and enhancement of the repair effect and the soothing effect are jointly achieved.

[0027] Example 4 An anti-allergy agent containing compound plant anti-allergy active ingredients, including the following components in parts by weight: 8 parts of bletilla striata extract, 10 parts of aloe vera extract, 9 parts of angelica sinensis extract, 15 parts of centella asiatica extract, 10 parts of rosemary extract, 12 parts of polygonum cuspidatum extract, 20 parts of scutellaria baicalensis extract, 7 parts of tea extract, 10 parts of licorice extract, 8 parts of chamomilla recutita extract, 8 parts of dendrobium officinale extract, and 6 parts of morus alba root bark extract.

[0028] Therefore, the addition of bletilla striata, aloe vera, and angelica sinensis forms a synergistic effect with the original components in a specific ratio.

[0029] Example 5 An anti-allergy agent containing compound plant anti-allergy active ingredients, including the following components in parts by weight: 8 parts of bletilla striata extract, 10 parts of aloe vera extract, 9 parts of angelica sinensis extract, 15 parts of centella asiatica extract, 10 parts of rosemary extract, 12 parts of polygonum cuspidatum extract, 20 parts of scutellaria baicalensis extract, 7 parts of tea extract, 10 parts of licorice extract, 8 parts of chamomilla recutita extract, 12 parts of dendrobium officinale extract, and 10 parts of morus alba root bark extract.

[0030] Therefore, the addition of bletilla striata, aloe vera, and angelica sinensis forms a synergistic effect with the original components in a specific ratio.

[0031] Example 6 An anti - allergy agent containing compound plant anti - allergy active ingredients, comprising the following components in parts by weight: 8 parts of Bletilla striata extract, 10 parts of Aloe vera extract, 9 parts of Angelica sinensis extract, 15 parts of Centella asiatica extract, 10 parts of Rosmarinus officinalis extract, 12 parts of Polygonum cuspidatum extract, 20 parts of Scutellaria baicalensis extract, 7 parts of tea extract, 10 parts of Glycyrrhiza glabra extract, 8 parts of Matricaria chamomilla extract, 10 parts of Dendrobium nobile extract and 8 parts of Morus alba root bark extract.

[0032] Among them, the polysaccharide component of Bletilla striata extract is used to synergistically enhance the skin barrier repair ability with Centella asiatica extract and promote epidermal cell regeneration; Aloe vera extract is used to combine with Matricaria chamomilla extract to inhibit skin erythema through anti - inflammatory activity and improve the moisturizing effect at the same time; Angelica sinensis extract is used to synergistically regulate the NF - κB inflammatory pathway with Scutellaria baicalensis extract, reduce the release of pro - inflammatory factor TNF - α, and strengthen the repair effect.

[0033] Therefore, the addition of Bletilla striata, Aloe vera, and Angelica sinensis forms a synergistic effect with the original components in a specific ratio. For example, Bletilla striata polysaccharide and Centella asiatica saponin jointly promote the migration of keratinocytes, aloe emodin and chamazulene inhibit the histamine release pathway, and ferulic acid of Angelica sinensis and baicalin jointly regulate the inflammatory signal pathway.

[0034] Example 7 The polysaccharide of Dendrobium nobile extract activates the AQP3 aquaporin to increase the epidermal water content, and synergistically enhances moisturization with the inhibition of hyaluronidase of Glycyrrhiza glabra; the dendrobine of Dendrobium nobile extract inhibits the over - activation of TRPV1 receptor to relieve the burning sensation, and forms a double - pathway of nerve sedation with the bisabolol of Matricaria chamomilla; Mulberroside of Morus alba root bark extract inhibits the release of tryptase from mast cells, and synergistically reduces the itching frequency with the histamine - blocking effect of Matricaria chamomilla; the ability of resveratrol oxide of Morus alba root bark extract to scavenge ROS is 2 times that of ordinary resveratrol, and jointly extends the antioxidant duration with EGCG of tea.

[0035] Example 8 A preparation method of an anti - allergy agent containing compound plant anti - allergy active ingredients, comprising the following steps: Step 1: Group extraction and concentration S1. Extract Centella asiatica, Rosmarinus officinalis and Polygonum cuspidatum by alcohol extraction 1). Mixed extraction Weigh Centella asiatica, Rosmarinus officinalis and Polygonum cuspidatum according to parts by weight, mix them evenly; add 6 - 8 times the total mass of the raw materials of 60% ethanol aqueous solution, reflux and extract at 70 - 75 °C for 2 times, 2 h each time; combine the two extraction solutions, filter through a 0.45 μm filter membrane to obtain an alcohol extract; 2). Concentration and drying The ethanol extract was concentrated under reduced pressure at 60 °C to a relative density of 1.15 - 1.20 to obtain an ethanol extract paste; it was spray-dried under the conditions of an inlet air temperature of 160 °C and an outlet air temperature of 80 °C to prepare an ethanol extract powder; S2. Extract Scutellaria baicalensis, tea, licorice, and chamomile by water extraction method 1). Extract separately Weigh Scutellaria baicalensis, tea, licorice, and chamomile by weight parts; add deionized water 10 times the mass of the raw materials respectively, decoct at 80 - 85 °C for 3 h, and filter while it is hot; 2). Combine and refine Combine the filtrates of Scutellaria baicalensis, tea, licorice, and chamomile, purify through macroporous adsorption resin of model AB - 8 to remove impurities; concentrate to a solid content of not less than 30% by weight percentage to obtain a water extract paste; Step 2. Compound additional components Select any one of the following components for compounding according to requirements to enhance the repair or soothing effect: S1. Repair synergistic group Add Bletilla striata extract, mix with Centella asiatica in the ethanol extract component in a ratio of 1:2 - 1:3, and synergistically promote the synthesis of stratum corneum lipids through β - glucan and asiaticoside; extract the Bletilla striata tuber by water extraction at a temperature of 80 - 95 °C, ultrafilter after extracting for 4 h, with a cut-off molecular weight of 10 kDa, and concentrate to a polysaccharide content of not less than 50%; S2. Soothing synergistic group Add Aloe vera extract, mix with chamomile extract in a ratio of 2:1 - 3:1, and use aloe emodin to inhibit the COX - 2 inflammatory pathway; after freeze-drying the aloe gel, extract it with 50% ethanol by ultrasonic extraction for 25 - 35 min, with an ultrasonic power of 300 W, to remove anthraquinone irritant components; S3. Anti-inflammatory synergistic group Add Angelica sinensis extract, jointly regulate the NF - κB pathway with Scutellaria baicalensis extract, and inhibit the release of TNF - α; percolate and extract the Angelica sinensis root with 70% ethanol, separate ferulic acid by silica gel column chromatography after concentration, so that the purity exceeds 90%; Step 3. Mix and form the preparation S1. Homogeneous mixing Mix the ethanol extract powder and the water extract paste in a mass ratio of 1:1 - 1:2, then add 0.5% - 1.5% carbomer, 1% - 3% glycerol, 0.1% - 0.3% phenoxyethanol; process with a homogenizer at a speed of 3000 rpm for 10 min to form a homogeneous slurry; S2. Dosage form processing 1). Gel dosage form, adjust the pH to 5.5 - 6.0, and fill it into a sterile aluminum tube; 2). Spray dosage form, add 5% - 8% azone, and subpackage it into a light-proof spray bottle; 3), Facial mask liquid, compounded with a non-woven fabric substrate and sterilized by cobalt-60 irradiation, with a dose of 10 kGy.

[0036] Example 9 This example is an addition based on Example 8: Before performing the step of grouped extraction and concentration in Step 1, select dry whole plants of Centella asiatica, rosemary leaves, rhizomes of Polygonum cuspidatum, roots of Scutellaria baicalensis, tea leaves, roots of Glycyrrhiza uralensis, and flowers of Matricaria chamomilla. After cleaning them respectively, dry them in a low-temperature environment of 40-50 °C and control the moisture content not to exceed 8%; crush the whole plants of Centella asiatica, rosemary leaves, rhizomes of Polygonum cuspidatum, roots of Scutellaria baicalensis, tea leaves, roots of Glycyrrhiza uralensis, and flowers of Matricaria chamomilla into particles of 20-40 mesh.

[0037] Example 10 This example is an addition based on Example 8: Before performing the step of grouped extraction and concentration in Step 1, select dry whole plants of Centella asiatica, rosemary leaves, rhizomes of Polygonum cuspidatum, roots of Scutellaria baicalensis, tea leaves, roots of Glycyrrhiza uralensis, and flowers of Matricaria chamomilla. After cleaning them respectively, dry them in a low-temperature environment of 45 °C and control the moisture content not to exceed 8%; crush the whole plants of Centella asiatica, rosemary leaves, rhizomes of Polygonum cuspidatum, roots of Scutellaria baicalensis, tea leaves, roots of Glycyrrhiza uralensis, and flowers of Matricaria chamomilla into particles of 33-37 mesh.

[0038] Example 11 In the step of compounding additional components in Step 2, select any one of the following groups of components for compounding according to requirements to enhance the repair or soothing effect: S1, Repair enhancement group Add Bletilla striata extract, mix it with Centella asiatica in the alcohol extraction component in a ratio of 1:2-1:3, and synergistically promote the synthesis of stratum corneum lipids through β-glucan and asiaticoside; extract the Bletilla striata tuber by water extraction at a temperature of 90 °C, ultrafilter it after 4 h of extraction, with a cut-off molecular weight of 10 kDa, and concentrate it to a polysaccharide content of not less than 50%; S2, Soothing enhancement group Add Aloe vera extract, mix it with Matricaria chamomilla extract in a ratio of 2:1-3:1, and use aloe-emodin to inhibit the COX-2 inflammatory pathway; after freeze-drying the aloe gel, extract it with 50% ethanol by ultrasonic extraction for 30 min, with an ultrasonic power of 300 W, to remove anthraquinone irritant components; S3, Anti-inflammatory synergistic group Add Angelica sinensis extract, jointly regulate the NF-κB pathway with Scutellaria baicalensis extract, and inhibit the release of TNF-α; extract the Angelica sinensis root by percolation with 70% ethanol, separate ferulic acid by silica gel column chromatography after concentration, so that the purity exceeds 90%.

[0039] Example 12 Application of an anti-allergy agent containing a compound plant anti-allergy active ingredient. The anti-allergy agent described in any one of Examples 1-7 with an addition amount of 1%-15% of the total mass is applied to allergic rhinitis nasal sprays, postoperative wound repair, pet skin anti-allergy sprays, anti-allergy baby clothing treatment agents, low-allergy household cleaners, and air purification sprays; Allergic rhinitis nasal spray: Chamomile bisabolol blocks the histamine receptor in the nasal mucosa and relieves symptoms such as sneezing and runny nose; Postoperative wound repair: Contains asiaticoside and resveratrol from polygonum cuspidatum, reducing postoperative scar hyperplasia; Pet skin anti-allergy spray: Aims at the itching caused by fleas and pollen in cats and dogs, with glycyrrhizic acid and chamomile extract as the core, which is safe and non-irritating; Anti-allergy baby clothing treatment agent: Adds licorice extract and tremella polysaccharide to neutralize detergent residues and reduce contact dermatitis in infants and young children; Low-allergy household cleaner: Replaces chemical surfactants, with rosmarinic acid and tea polyphenols as the core, reducing the irritation of the cleaner to the skin; Air purification spray: Contains antioxidant components from polygonum cuspidatum and calming components from chamomile, decomposing indoor allergens (such as pollen and pet dander).

[0040] The formula compositions of Examples 1-6 are as shown in Table 1 below: Table 1

[0041] For Examples 1, 4, and 6, a soothing efficacy test - detection of the content of inflammatory factors (TNF-α, IL-6, IL-1α) in UVB-stimulated keratinocytes and a repair efficacy test - keratinocyte migration ability test were carried out.

[0042] Among them, the soothing efficacy test - detection of the content of inflammatory factors (TNF-α, IL-6, IL-1α) in UVB-stimulated keratinocytes and the repair efficacy test - keratinocyte migration ability test of Example 4 are as follows: I. Test items: Soothing efficacy test - detection of the content of inflammatory factors (TNF-α, IL-6, IL-1α) in UVB-stimulated keratinocytes.

[0043] 1. Test materials 1.1 Test system Human immortalized keratinocytes (HaCaT).

[0044] 1.2 Main reagents High-glucose DMEM medium (Gibco), fetal bovine serum (Gibco), PBS (VivaCell), MTT (Sigma), DMSO (Sinopharm), trypsin (Gibco), Human IL-1α ELISA Kit (Absin), Human IL-6 ELISA Kit (NOVUS), Human TNF-α ELISA Kit (BOSTER).

[0045] 1.3 Main equipment CO2 incubator (Thermo, 160i), biological safety cabinet (Sujing Antai, BSC-1604ⅡA2), inverted fluorescence microscope (Keyence BZ-X810), microplate reader (Tecan, Spark), ultraviolet light therapy instrument (SS-03).

[0046] 1.4 Sample information The sample information is as follows: The anti-allergic agent containing the compound plant anti-allergic active ingredient in Example 4 was prepared into a sample.

[0047] 2. Testing methods 2.1 Cytotoxicity 1). Cell seeding: Cells were seeded into 96-well plates at an inoculation density of 1×10 4 cells / well and incubated overnight in an incubator (37°C, 5% CO2).

[0048] 2). Experimental grouping: The experimental setup included a zero control group, a control group, a positive control group, and a sample group. In the sample group, 8 concentration gradients were set for each sample, and 3 replicate wells were set for each concentration gradient.

[0049] 3). Solution preparation: Different concentrations of sample working solutions were prepared according to the test concentration setting table.

[0050] Table 2 Test concentration setting table

[0051] 4). Administration: Administration was carried out when the cell confluence rate in the 96-well plates reached 40% - 60%. In the control group, 200 µL of the culture medium containing 10% PBS was added to each well; in the positive control group, 200 µL of the culture medium containing 10% DMSO was added to each well; in the sample group, 200 µL of the culture medium containing the corresponding concentration of the sample was added to each well; in the zero control group, no cells were seeded, and only 200 µL of the cell culture medium was added. After administration, the 96-well plates were placed in an incubator (37°C, 5% CO2) for culture.

[0052] 5), Detection: After 24 h of cell incubation, discard the supernatant, add MTT working solution (0.5 mg / mL), incubate in the dark at 37 °C for 4 h. After incubation, discard the supernatant, add 100 μL DMSO to each well, and read the OD value at 490 nm.

[0053] 6), Calculation of cell viability: Calculate according to the formula

[0054] 2.2 Measurement of inflammatory factor content The specific experimental grouping is set as shown in Table 3 Table 3 Experimental design

[0055] 1), Cell seeding: Seed cells into a 24-well plate at an inoculation density of 1×10 5 cells / well and incubate overnight in an incubator (37 °C, 5% CO2).

[0056] 2), Preparation of solutions: Prepare working solutions of test substances at different concentrations according to the experimental design table.

[0057] 3), Administration: According to the experimental design table, when the cell confluence rate in the 24-well plate reaches 40%-60%, perform grouped administration, with 3 replicates in each group. Add 1 mL of cell culture medium to each well in the blank control group and negative control group; add 1 mL of cell culture medium containing 100 μg / mL dexamethasone to each well in the positive control group; add 1 mL of cell culture medium containing the corresponding concentration of test substance to each well in the sample group.

[0058] 4), Radiation: After administration, the negative control group, positive control group, and sample group receive UVB radiation with a total dose of 300 mJ / cm 2 , while the blank control group is placed in the same environment (UVB radiation dose is 0 mJ / cm 2 ), and continue to culture in an incubator (37 °C, 5% CO2) for 24 h.

[0059] 5), Sample collection: After incubation, collect the cell culture supernatant into an EP tube (Note: Determine the amount of sample collected according to the detection index), and place the sample in a -80 °C refrigerator for freezing and storage after collection.

[0060] 6), Detection of IL-1α content: Detect according to the operation manual of the Human IL-1α ELISA kit.

[0061] 7), Detection of IL-6 content: Detect according to the operation manual of the Human IL-6 ELISA kit.

[0062] 8), Detection of TNF-α content: Detection was carried out according to the operating instructions of the Human TNF-α ELISA kit.

[0063] 3. Test Results 3.1 Cytotoxicity Test Results Cytotoxicity detection experiments were carried out at the 8 dosing concentrations set for the samples in Table 2, and the MTT detection results are shown in Table 4.

[0064] Table 4 MTT Detection Results

[0065] Using the 8 concentrations selected for the samples as the abscissa and the cell viability value as the ordinate, a cell viability graph was plotted (see Figure 1 ).

[0066] Therefore, according to the MTT results, the sample compound highly effective anti-allergy agent did not show cytotoxicity to keratinocytes within the concentration range of 2.500% (V / V).

[0067] 3.2 IL-1α Content Test Results Based on the experimental method, cell supernatants were collected for IL-1α content detection, and the detection results are shown in Table 5, and the change trend is as Figure 2 shown.

[0068] Table 5 IL-1α Data Summary Table

[0069] Note: When performing statistical analysis using the t-test two-tailed test method, when comparing the NC group with the BC group, the significance is indicated by #, p-value < 0.05 is indicated by #, and p-value < 0.01 is indicated by ##. When comparing the sample group, the PC group with the NC group, the significance is indicated by *, p-value < 0.05 is indicated by *, and p-value < 0.01 is indicated by **.

[0070] Figure 2 Among them: Compared with the BC group, the secretion of the keratinocyte inflammatory factor IL-1α in the NC group increased significantly (p < 0.01), indicating that the UVB stimulation model was successfully established in this experiment.

[0071] Compared with the NC group, at the dosing concentration of 100 μg / mL dexamethasone, the secretion of the keratinocyte inflammatory factor IL-1α in the PC group decreased significantly (p < 0.01), indicating that the positive control detection in this experiment was effective.

[0072] Compared with the NC group, when the sample was at concentrations of 0.625%, 1.250% and 2.500% (V / V), the secretion of the keratinocyte inflammatory factor IL-1α decreased significantly (p < 0.01).

[0073] 3.3 IL-6 content test results Based on the experimental method, cell supernatants were collected and the IL-6 content was detected. The detection results are shown in Table 6, and the trend is shown in Figure 3.

[0074] Table 6 IL-6 data summary table

[0075] Note: When performing statistical analysis using the t-test two-tailed test method, when comparing the NC group with the BC group, the significance is indicated by #, p-value < 0.05 is indicated by #, and p-value < 0.01 is indicated by ##. When comparing the sample group and the PC group with the NC group, the significance is indicated by *, p-value < 0.05 is indicated by *, and p-value < 0.01 is indicated by **.

[0076] Figure 3 Among them: Compared with the BC group, the secretion of the keratinocyte inflammatory factor IL-6 in the NC group increased significantly (p < 0.01), indicating that the UVB stimulation model was successfully established in this experiment.

[0077] Compared with the NC group, at the administration concentration of 100 μg / mL dexamethasone, the secretion of the keratinocyte inflammatory factor IL-6 in the PC group decreased significantly (p < 0.01), indicating that the positive control test in this experiment was effective.

[0078] Compared with the NC group, when the sample concentration was 0.625%, 1.250% and 2.500% (V / V), the secretion of the keratinocyte inflammatory factor IL-6 decreased significantly (p < 0.01).

[0079] 3.4 TNF-α content test results Based on the experimental method, cell supernatants were collected and the TNF-α content was detected. The detection results are shown in Table 7, and the trend is as Figure 4 shown.

[0080] Table 7 TNF-α data summary table

[0081] Note: When performing statistical analysis using the t-test two-tailed test method, when comparing the NC group with the BC group, the significance is indicated by #, p-value < 0.05 is indicated by #, and p-value < 0.01 is indicated by ##. When comparing the sample group and the PC group with the NC group, the significance is indicated by *, p-value < 0.05 is indicated by *, and p-value < 0.01 is indicated by **.

[0082] Figure 4Among them, compared with the BC group, the secretion level of the keratinocyte inflammatory factor TNF-α in the NC group increased significantly (p<0.01), indicating that the UVB-stimulated model was successfully established in this experiment.

[0083] Compared with the NC group, at the administration concentration of 100 μg / mL dexamethasone, the secretion level of the keratinocyte inflammatory factor TNF-α in the PC group decreased significantly (p<0.01), indicating that the positive control test in this experiment was effective.

[0084] Compared with the NC group, when the sample concentrations were 0.625%, 1.250% and 2.500% (V / V), the secretion level of the keratinocyte inflammatory factor TNF-α decreased significantly (p<0.01).

[0085] 4. Conclusions Based on the UVB-stimulated human immortalized keratinocyte (HaCaT) model, when the concentrations of the sample anti-allergic agent in Example 4 were 0.625%, 1.250% and 2.500% (V / V), the contents of the keratinocyte inflammatory factors IL-1α, IL-6 and TNF-α decreased significantly, and there were statistical differences compared with the NC group (p<0.01), indicating that the sample compound high-efficiency anti-allergic agent could inhibit the secretion of the keratinocyte inflammatory factors IL-1α, IL-6 and TNF-α and had a soothing effect.

[0086] II. Test items: Repair efficacy test - Keratinocyte migration ability test.

[0087] 1. Test materials 1.1 Test system Human immortalized keratinocytes (HaCaT).

[0088] 1.2 Main reagents High-glucose DMEM culture medium (Gibco), fetal bovine serum (Gibco), PBS (VivaCell), MTT (Sigma), trypsin (Gibco), DMSO (Sinopharm).

[0089] 1.3 Main equipment CO2 incubator (Thermo, 160i), biological safety cabinet (ESCO, LA2-6A1), inverted fluorescence microscope (Keyence BZ-X810), microplate reader (Tecan, Spark).

[0090] 1.4 Sample information The sample information is as follows: The anti-allergic agent containing the compound plant anti-allergic active ingredient in Example 4 was prepared into a sample.

[0091] 2. Test methods 2.1 Cytotoxicity 1), Cell seeding: Seed cells into a 96-well plate at a seeding density of 1×10 4 cells / well and incubate overnight in an incubator (37 °C, 5% CO2).

[0092] 2), Experimental grouping: Set up a zero control group, a control group, a positive control group, and a sample group. In the sample group, set 8 concentration gradients for each sample, and set 3 replicate wells for each concentration gradient.

[0093] 3), Solution preparation: Prepare sample working solutions at different concentrations according to the test concentration setting table.

[0094] Table 8 Test concentration setting table

[0095] 4), Drug administration: Administer drugs when the cell confluence rate in the 96-well plate reaches 40%-60%. Add 200 μL of culture medium containing 10% PBS to each well in the control group; add 200 μL of culture medium containing 10% DMSO to each well in the positive control group; add 200 μL of culture medium containing the corresponding concentration of the sample to each well in the sample group; no cells are seeded in the zero control group, and only 200 μL of cell culture medium is added. After drug administration, place the 96-well plate in an incubator (37 °C, 5% CO2) for culture.

[0096] 5), Detection: After 24 h of cell incubation, discard the supernatant, add medium containing 0.5 mg / mL of MTT, incubate at 37 °C in the dark for 4 h. After incubation, discard the supernatant, add 100 μL of DMSO to each well, and read the OD value at 490 nm.

[0097] 6), Calculation of cell viability: Calculate according to the formula

[0098] 2.2 Cell migration test 1), Collect cells in the logarithmic growth phase and seed them into a 24-well culture plate at a cell density of 1.5×10 5 cells / well.

[0099] 2), After culturing in an incubator (37 °C, 5% CO2) for 24 h, use a 200 μL pipette tip to make a horizontal scratch perpendicular to the 24-well plate, wash the cells once with PBS to remove the scratched cells.

[0100] 3), Load samples according to Table 9. Place them in an incubator (37 °C, 5% CO2) for 24 h, and set 3 parallels for each group.

[0101] Table 9 Experimental design

[0102] 4), Use an inverted microscope to take pictures of the migrated cells in each group, and use Image Pro Plus software to calculate the average value of the scratch area.

[0103]

[0104] 3. Test Results 3.1 Cytotoxicity Test Results Set 8 dosing concentrations according to the samples in Table 8 and conduct a cytotoxicity detection experiment. The MTT test results are shown in Table 4.

[0105] Using the 8 concentrations selected for the sample as the abscissa and the cell viability value as the ordinate, draw a cell viability graph (see Figure 1 ).

[0106] Therefore, according to the MTT results, the sample compound high-efficiency anti-allergy agent did not show cytotoxicity to keratinocytes within the concentration range of 2.500% (V / V).

[0107] 3.2 Cell Migration Test Results The test results are shown in Figure 5 , and the result analysis is shown in Table 10 and Figure 6 .

[0108] Table 10 is the summary table of cell healing rate results

[0109] Note: When using the t-test two-tailed test method for statistical analysis, compared with the BC group, the significance of the sample group and the PC group is indicated by *, p-value < 0.05 is indicated by *, and p-value < 0.01 is indicated by **.

[0110] Figure 6 In the cell migration test, the cell healing level of the PC group was significantly higher than that of the BC group (p < 0.01), indicating that the positive control test was effective this time; compared with the BC group, after treatment with the sample at concentrations of 0.625%, 1.250%, and 2.500% (V / V), the cell healing rate increased significantly (p < 0.05).

[0111] 4. Conclusion Based on the human immortalized keratinocyte (HaCaT) model, after treatment with the sample compound high-efficiency anti-allergy agent at concentrations of 0.625%, 1.250%, and 2.500% (V / V) for 24 h, the cell healing rate of keratinocytes increased significantly, and there was a statistical difference compared with the BC group (p < 0.05), indicating that the sample compound high-efficiency anti-allergy agent can promote the cell healing of keratinocytes and has a repair effect.

[0112] In addition, Example 1 and Example 6 were also subjected to a soothing efficacy test - detection of the contents of inflammatory factors (TNF-α, IL-6, IL-1α) in UVB-stimulated keratinocytes and a repair efficacy test - keratinocyte migration ability test in the same testing manner as in Example 4. The specific test results are as follows: The specific results of the soothing efficacy test - detection of the contents of inflammatory factors (TNF-α, IL-6, IL-1α) in UVB-stimulated keratinocytes in Example 1 are as follows: 1. A cytotoxicity detection experiment was carried out, and the MTT detection results are shown in Table 11.

[0113] Table 11 MTT detection results

[0114] According to the MTT results, the sample compound highly effective anti-allergy agent did not show keratinocyte toxicity within the concentration range of 2.500% (V / V).

[0115] 2. IL-1α content test results Based on the experimental method, cell supernatants were collected for IL-1α content detection. The detection results are shown in Table 12, and the change trend is as Figure 7 shown.

[0116] Table 12 IL-1α data summary table

[0117] Note: When performing statistical analysis using the t-test two-tailed test method, compared with the BC group, the significance in the NC group is indicated by #, p-value < 0.05 is indicated by #, and p-value < 0.01 is indicated by ##. Compared with the NC group, the significance in the sample group and the PC group is indicated by *, p-value < 0.05 is indicated by *, and p-value < 0.01 is indicated by **.

[0118] Figure 7 Among them: compared with the BC group, the secretion amount of the keratinocyte inflammatory factor IL-1α in the NC group increased significantly (p < 0.01), indicating that the UVB stimulation model was successfully established in this experiment.

[0119] Compared with the NC group, at the administration concentration of 100 μg / mL dexamethasone in the PC group, the secretion amount of the keratinocyte inflammatory factor IL-1α decreased significantly (p < 0.01), indicating that the positive control detection in this experiment was effective.

[0120] Compared with the NC group, when the sample was at concentrations of 0.625%, 1.250%, and 2.500% (V / V), the secretion amount of the keratinocyte inflammatory factor IL-1α decreased significantly (p < 0.01).

[0121] 3. IL-6 Content Test Results Based on the experimental method, cell supernatants were collected and the IL-6 content was detected. The test results are shown in Table 13, and the trend is as Figure 8 shown.

[0122] Table 13 Summary Table of IL-6 Data

[0123] Note: When using the t-test two-tailed test method for statistical analysis, compared with the BC group, the significance of the NC group is indicated by #, p-value < 0.05 is indicated by #, and p-value < 0.01 is indicated by ##. When comparing the sample group and the PC group with the NC group, the significance is indicated by *, p-value < 0.05 is indicated by *, and p-value < 0.01 is indicated by **.

[0124] Figure 8 Among them: compared with the BC group, the secretion of the keratinocyte inflammatory factor IL-6 in the NC group increased significantly (p < 0.01), indicating that the UVB stimulation model was successfully established in this experiment.

[0125] Compared with the NC group, at the administration concentration of 100 μg / mL dexamethasone, the secretion of the keratinocyte inflammatory factor IL-6 in the PC group decreased significantly (p < 0.01), indicating that the positive control test in this experiment was effective.

[0126] Compared with the NC group, when the sample concentration was 0.625%, 1.250% and 2.500% (V / V), the secretion of the keratinocyte inflammatory factor IL-6 decreased significantly (p < 0.01).

[0127] 4. TNF-α Content Test Results Based on the experimental method, cell supernatants were collected and the TNF-α content was detected. The test results are shown in Table 14, and the trend is as Figure 9 shown.

[0128] Table 14 Summary Table of TNF-α Data

[0129] Note: When using the t-test two-tailed test method for statistical analysis, compared with the BC group, the significance of the NC group is indicated by #, p-value < 0.05 is indicated by #, and p-value < 0.01 is indicated by ##. When comparing the sample group and the PC group with the NC group, the significance is indicated by *, p-value < 0.05 is indicated by *, and p-value < 0.01 is indicated by **.

[0130] Figure 9In the NC group, the secretion level of the keratinocyte inflammatory factor TNF-α increased significantly compared with that in the BC group (p < 0.01), indicating that the UVB-stimulated model was successfully established in this experiment.

[0131] Compared with the NC group, at the administration concentration of 100 μg / mL dexamethasone, the secretion level of the keratinocyte inflammatory factor TNF-α in the PC group decreased significantly (p < 0.01), indicating that the positive control test in this experiment was effective.

[0132] Compared with the NC group, when the concentration of the sample was 0.625%, 1.250%, and 2.500% (V / V), the secretion level of the keratinocyte inflammatory factor TNF-α decreased significantly (p < 0.01).

[0133] 5. Conclusion Based on the UVB-stimulated human immortalized keratinocyte (HaCaT) model, when the concentration of the sample anti-allergic agent in Example 1 was 0.625%, 1.250%, and 2.500% (V / V), the contents of the keratinocyte inflammatory factors IL-1α, IL-6, and TNF-α all decreased significantly, and there was a statistical difference compared with the NC group (p < 0.01), indicating that the sample compound high-efficiency anti-allergic agent could inhibit the secretion of the keratinocyte inflammatory factors IL-1α, IL-6, and TNF-α and had a soothing effect.

[0134] The specific results of the repair efficacy test - keratinocyte migration ability test in Example 1 are as follows: 1. Results of the cytotoxicity test Eight administration concentrations were set for the sample, and a cytotoxicity detection experiment was carried out. The MTT detection results are shown in Table 11.

[0135] According to the MTT results, the sample compound high-efficiency anti-allergic agent did not show keratinocyte toxicity within the concentration range of 2.500% (V / V).

[0136] 2. Results of the cell migration test The analysis of the test results is shown in Table 15 and Figure 10 .

[0137] Table 15 is the summary table of the cell healing rate results

[0138] Note: When the t-test two-tailed test method was used for statistical analysis, compared with the BC group, the significance in the sample group and the PC group was indicated by *, p-value < 0.05 was indicated by *, and p-value < 0.01 was indicated by **.

[0139] Figure 10In the cell migration assay, the cell healing level of the PC group was significantly higher than that of the BC group (p < 0.01), indicating that the positive control test was effective in this experiment. Compared with the BC group, the cell healing rate was significantly increased after treatment with samples at concentrations of 0.625%, 1.250%, and 2.500% (V / V) (p < 0.05).

[0140] 3. Conclusion Based on the human immortalized keratinocyte (HaCaT) model, after treatment with the sample compound high-efficiency anti-allergy agent at concentrations of 0.625%, 1.250%, and 2.500% (V / V) for 24 h, the cell healing rate of keratinocytes was significantly increased, and there was a statistical difference compared with the BC group (p < 0.05), indicating that the sample compound high-efficiency anti-allergy agent can promote the cell healing of keratinocytes and has a repair effect.

[0141] The specific results of the soothing effect test of Example 6 - detection of the contents of inflammatory factors (TNF-α, IL-6, IL-1α) in UVB-stimulated keratinocytes are as follows: 1. Conduct a cytotoxicity detection experiment, and the MTT detection results are shown in Table 16.

[0142] Table 16 MTT detection results

[0143] 2. Test results of IL-1α content Based on the experimental method, cell supernatants were collected for IL-1α content detection, and the detection results are shown in Table 17, and the change trend is as Figure 11 shown.

[0144] Table 17 Summary table of IL-1α data

[0145] Note: When using the t-test two-tailed test method for statistical analysis, compared with the BC group, the significance of the NC group is indicated by #, p-value < 0.05 is indicated by #, and p-value < 0.01 is indicated by ##. Compared with the NC group, the significance of the sample group and the PC group is indicated by *, p-value < 0.05 is indicated by *, and p-value < 0.01 is indicated by **.

[0146] Figure 11 Among them: compared with the BC group, the secretion amount of the inflammatory factor IL-1α in keratinocytes of the NC group was significantly increased (p < 0.01), indicating that the UVB-stimulated model was successfully established in this experiment.

[0147] Compared with the NC group, in the PC group at the dexamethasone administration concentration of 100 μg / mL, the secretion of the keratinocyte inflammatory factor IL-1α was significantly decreased (p<0.01), indicating that the positive control test was effective this time.

[0148] Compared with the NC group, when the sample concentrations were 0.625%, 1.250%, and 2.500% (V / V), the secretion of the keratinocyte inflammatory factor IL-1α was significantly decreased (p<0.01).

[0149] 3. Test results of IL-6 content Based on the experimental method, cell supernatants were collected for IL-6 content detection. The detection results are shown in Table 18, and the change trend is as Figure 12 shown.

[0150] Table 18 Summary table of IL-6 data

[0151] Note: When performing statistical analysis using the two-tailed t-test method, compared with the BC group, the significance in the NC group is indicated by #, p-value < 0.05 is indicated by #, and p-value < 0.01 is indicated by ##. When comparing the sample group, the PC group with the NC group, the significance is indicated by *, p-value < 0.05 is indicated by *, and p-value < 0.01 is indicated by **.

[0152] Figure 12 Among them: Compared with the BC group, the secretion of the keratinocyte inflammatory factor IL-6 in the NC group was significantly increased (p<0.01), indicating that the UVB stimulation model was successfully established in this experiment.

[0153] Compared with the NC group, in the PC group at the dexamethasone administration concentration of 100 μg / mL, the secretion of the keratinocyte inflammatory factor IL-6 was significantly decreased (p<0.01), indicating that the positive control test was effective this time.

[0154] Compared with the NC group, when the sample concentrations were 0.625%, 1.250%, and 2.500% (V / V), the secretion of the keratinocyte inflammatory factor IL-6 was significantly decreased (p<0.01).

[0155] 4. Test results of TNF-α content Based on the experimental method, cell supernatants were collected for TNF-α content detection. The detection results are shown in Table 19, and the change trend is as Figure 13 shown.

[0156] Table 19 Summary table of TNF-α data

[0157] Note: When performing statistical analysis using the t-test two-tailed test method, compared with the BC group, the significance is indicated by # for the NC group, # for p-value < 0.05, and ## for p-value < 0.01. When comparing the sample group and the PC group with the NC group, the significance is indicated by *, * for p-value < 0.05, and ** for p-value < 0.01.

[0158] Figure 13 Among them, compared with the BC group, the secretion level of the keratinocyte inflammatory factor TNF-α in the NC group increased significantly (p < 0.01), indicating that the UVB-stimulated model was successfully established in this experiment.

[0159] Compared with the NC group, at the administration concentration of 100 μg / mL dexamethasone, the secretion level of the keratinocyte inflammatory factor TNF-α in the PC group decreased significantly (p < 0.01), indicating that the positive control test in this experiment was effective.

[0160] Compared with the NC group, when the sample was at concentrations of 0.625%, 1.250%, and 2.500% (V / V), the secretion level of the keratinocyte inflammatory factor TNF-α decreased significantly (p < 0.01).

[0161] 5. Conclusion Based on the UVB-stimulated human immortalized keratinocyte (HaCaT) model, when the sample anti-allergic agent in Example 6 was at concentrations of 0.625%, 1.250%, and 2.500% (V / V), the contents of the keratinocyte inflammatory factors IL-1α, IL-6, and TNF-α all decreased significantly, and there was a statistical difference compared with the NC group (p < 0.01), indicating that the sample compound high-efficiency anti-allergic agent can inhibit the secretion of the keratinocyte inflammatory factors IL-1α, IL-6, and TNF-α and has a soothing effect.

[0162] The specific results of the repair efficacy test - keratinocyte migration ability test in Example 6 are as follows: 1. Results of cytotoxicity test Eight administration concentrations were set for the sample, and a cytotoxicity detection experiment was carried out. The MTT detection results are shown in Table 16.

[0163] According to the MTT results, the sample compound high-efficiency anti-allergic agent did not show cytotoxicity to keratinocytes within the concentration range of 2.500% (V / V).

[0164] 2. Results of cell migration test The analysis of the test results is shown in Table 20 and Figure 14 .

[0165] Table 20 is the summary table of cell healing rate results

[0166] Note: When using the t-test two-tailed test method for statistical analysis, when comparing the sample group, PC group and BC group, the significance is indicated by *, p-value < 0.05 is indicated by *, and p-value < 0.01 is indicated by **.

[0167] Figure 14 In the cell migration assay, the cell healing level of the PC group was significantly higher than that of the BC group (p < 0.01), indicating that the positive control test was effective this time; compared with the BC group, the cell healing rate was significantly increased after treatment with the samples at concentrations of 0.625%, 1.250%, and 2.500% (V / V) (p < 0.05).

[0168] 3. Conclusion Based on the human immortalized keratinocyte (HaCaT) model, after treatment with the sample compound highly effective anti-allergy agent at concentrations of 0.625%, 1.250%, and 2.500% (V / V) for 24 h, the cell healing rate of keratinocytes was significantly improved, and there was a statistical difference compared with the BC group (p < 0.05), indicating that the sample compound highly effective anti-allergy agent can promote the cell healing of keratinocytes and has a repair effect.

[0169] Example 13 An anti-allergy agent containing a compound plant anti-allergy active ingredient, comprising the following components in parts by weight: 5 parts of sanguisorba officinalis extract, 7 parts of lithospermum erythrorhizon, 8 parts of bletilla striata extract, 10 parts of aloe vera extract, 9 parts of angelica sinensis extract, 15 parts of centella asiatica extract, 10 parts of rosemary extract, 12 parts of polygonum cuspidatum extract, 20 parts of scutellaria baicalensis extract, 7 parts of tea extract, 10 parts of glycyrrhiza glabra extract, 8 parts of chamomilla recutita extract, 8 parts of dendrobium officinale extract, and 6 parts of morus alba root bark extract.

[0170] Therefore, by combining the blood vessel repair of sanguisorba officinalis and the epidermal regeneration of lithospermum erythrorhizon, it targets the "deep inflammation - surface damage" linkage repair, breaking through the traditional single anti-inflammatory or collagen-promoting ideas.

[0171] In the description of the present invention, although the embodiments of the present invention have been shown and described, for those of ordinary skill in the art, it can be understood that various changes, modifications, substitutions, and variations can be made to these embodiments without departing from the principles and spirits of the present invention, and the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. An anti-allergy agent containing a compound plant anti-allergy active ingredient, characterized in that, Comprising the following components in parts by weight: Bletilla striata extract 5 - 10 parts, Aloe vera extract 8 - 15 parts, Angelica sinensis extract 7 - 12 parts, Centella asiatica extract 10 - 20 parts, Rosmarinus officinalis extract 5 - 15 parts, Polygonum cuspidatum extract 8 - 18 parts, Scutellaria baicalensis extract 12 - 25 parts, Tea extract 3 - 10 parts, Glycyrrhiza glabra extract 6 - 15 parts, and Matricaria chamomilla extract 4 - 12 parts; Among them, the polysaccharide component of the Bletilla striata extract is used to synergistically enhance the skin barrier repair ability with the Centella asiatica extract and promote epidermal cell regeneration; the Aloe vera extract is used to combine with the Matricaria chamomilla extract to inhibit skin erythema through anti-inflammatory activity and simultaneously improve the moisturizing effect; the Angelica sinensis extract is used to synergistically regulate the NF-κB inflammatory pathway with the Scutellaria baicalensis extract, reduce the release of pro-inflammatory factor TNF-α, and strengthen the repair effect.

2. The anti-allergy agent containing the compound plant anti-allergy active ingredient according to claim 1, characterized in that, The anti-allergy agent containing the compound plant anti-allergy active ingredient comprises the following components in parts by weight: Bletilla striata extract 8 parts, Aloe vera extract 10 parts, Angelica sinensis extract 9 parts, Centella asiatica extract 15 parts, Rosmarinus officinalis extract 10 parts, Polygonum cuspidatum extract 12 parts, Scutellaria baicalensis extract 20 parts, Tea extract 7 parts, Glycyrrhiza glabra extract 10 parts, and Matricaria chamomilla extract 8 parts.

3. The anti-allergy agent containing the compound plant anti-allergy active ingredient according to claim 1 or 2, characterized in that, It further comprises the following components in parts by weight: Dendrobium officinale extract 8 - 12 parts and Morus alba root bark extract 6 - 10 parts.

4. The anti-allergy agent containing the compound plant anti-allergy active ingredient according to claim 3, characterized in that, It further comprises the following components in parts by weight: Dendrobium officinale extract 10 parts and Morus alba root bark extract 8 parts.

5. The anti-allergy agent containing the compound plant anti-allergy active ingredient according to claim 4, characterized in that The polysaccharide of the Dendrobium officinale extract activates the AQP3 aquaporin to increase the epidermal water content, and synergistically enhances moisturization with the hyaluronidase inhibition of Glycyrrhiza glabra; the dendrobine of the Dendrobium officinale extract inhibits the over-activation of TRPV1 receptors, relieves the burning sensation, and forms a double neural sedative pathway with the bisabolol of Matricaria chamomilla; The mulberroside of the Morus alba root bark extract inhibits the release of tryptase from mast cells, and synergistically reduces the itching frequency with the histamine-blocking effect of Matricaria chamomilla; the resveratrol oxide of the Morus alba root bark extract has 2 times the ROS-scavenging ability of ordinary resveratrol, and jointly with the EGCG of tea extends the antioxidant duration.

6. A method for preparing an anti-allergy agent containing a compound plant anti-allergy active ingredient according to claim 1 or 2, characterized in that, Comprising the following steps: Weigh Centella asiatica, Rosmarinus officinalis, and Polygonum cuspidatum according to parts by weight, mix evenly; add 60% ethanol aqueous solution 6 - 8 times the total mass of the raw materials, reflux and extract at 70 - 75 °C for 2 times, each time for 2 h; combine the two extraction solutions, filter through a 0.45 μm filter membrane to obtain an ethanol extract; Concentrate the ethanol extract under reduced pressure at 60 °C to a relative density of 1.15 - 1.20 to obtain an ethanol extract paste; spray-dry under the conditions of an inlet air temperature of 160 °C and an outlet air temperature of 80 °C to make an ethanol extract powder; Weigh Scutellaria baicalensis, tea, Glycyrrhiza glabra, and Matricaria chamomilla according to parts by weight; respectively add deionized water 10 times the mass of the raw materials, decoct at 80 - 85 °C for 3 h, and filter while it is hot; combine the filtrates of Scutellaria baicalensis, tea, Glycyrrhiza glabra, and Matricaria chamomilla, purify through macroporous adsorption resin of type AB-8 to remove impurities; concentrate to a solid content by weight percentage of not less than 30% to obtain a water extract paste.

7. The preparation method of the anti-allergy agent containing the compound plant anti-allergy active ingredient according to claim 6, characterized in that, Select the dried whole plant of Centella asiatica, rosemary leaves, rhizome of Polygonum cuspidatum, root of Scutellaria baicalensis, tea leaves, licorice root and chamomile flowers. After cleaning respectively, dry them in a low-temperature environment of 40-50°C and control the moisture content not to exceed 8%; crush the whole plant of Centella asiatica, rosemary leaves, rhizome of Polygonum cuspidatum, root of Scutellaria baicalensis, tea leaves, licorice root and chamomile flowers into particles of 20-40 mesh.

8. The preparation method of the anti-allergy agent containing the compound plant anti-allergy active ingredient according to claim 7, characterized in that, Select the dried whole plant of Centella asiatica, rosemary leaves, rhizome of Polygonum cuspidatum, root of Scutellaria baicalensis, tea leaves, licorice root and chamomile flowers. After cleaning respectively, dry them in a low-temperature environment of 45°C and control the moisture content not to exceed 8%; crush the whole plant of Centella asiatica, rosemary leaves, rhizome of Polygonum cuspidatum, root of Scutellaria baicalensis, tea leaves, licorice root and chamomile flowers into particles of 33-37 mesh.

9. The preparation method of the anti-allergy agent containing the compound plant anti-allergy active ingredient according to claim 6, characterized in that, It also includes compound additional components. Select any one of the following components for compounding according to needs to enhance the repair or soothing effect: S1, Repair enhancement group Add Bletilla striata extract and mix it with Centella asiatica in the alcohol extraction component in a ratio of 1:2-1:

3. Synergistically promote the synthesis of stratum corneum lipids through β-glucan and asiaticoside; Extract the Bletilla striata tuber by water extraction at a temperature of 90°C, ultrafilter after extracting for 4 h, with a cut-off molecular weight of 10 kDa, and concentrate to a polysaccharide content of not less than 50%. S2, Soothing enhancement group Add aloe extract and mix it with chamomile extract in a ratio of 2:1-3:

1. Use aloe-emodin to inhibit the COX-2 inflammatory pathway; After freeze-drying the aloe gel, extract it by ultrasonic extraction with 50% ethanol for 30 min, with an ultrasonic power of 300W, to remove anthraquinone irritant components. S3, Anti-inflammatory synergistic group Add angelica extract and jointly regulate the NF-κB pathway with Scutellaria baicalensis extract to inhibit the release of TNF-α; Extract the angelica root by percolation with 70% ethanol, concentrate and separate ferulic acid by silica gel column chromatography to make the purity exceed 90%.

10. Use of an anti-allergy agent containing a compound plant anti-allergy active ingredient, characterized in that, Apply the anti-allergy agent containing the compound plant anti-allergy active ingredient described in claim 1 or 2 to allergic rhinitis nasal sprays, postoperative wound repair, pet skin anti-allergy sprays, anti-allergy baby clothing treatment agents, low-allergy household cleaners and air purification sprays.

Images